![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
Objective: To examine hospitalisation rates and resource utilisation following initiation of risperidone long-acting therapy (RLAT) among US veterans with schizophrenia.
Methods: Encounter data were analysed from the Ohio Veterans Affairs (VA) Healthcare System. Adult patients (schizophrenia or schizoaffective disorder) with ≥1 medical or hospital visits with a diagnosis code of 295.xx, continuous enrolment from January 2003 through January 2006, and ≥4 injections of RLAT were selected. Analyses compared psychiatric-related resource utilisation pre- and post-exposure to RLAT; each patient served as his/her own control. The pre-exposure and post-exposure periods defined were equal in duration (e.g., a 6-month post-exposure period was matched with a 6-month pre-exposure period). Descriptive and comparative analyses (paired t tests, McNemar's test) were performed.
Results: Patients (n=106) were 51.9 years old (±10.2), male (93%), white (73%) and received on average 14 RLAT doses (±9.7; range, 4–47 injections) over 309 days (±196; range, 42–737 days). Most experienced a psychiatric-related hospitalisation prior to initiation; less than half experienced hospitalisation after initiation (75% vs. 42%; p<0.001). Relative to pre-initiation, fewer psychiatric-related hospitalisations (mean [SD] change, –0.8 [2.0]; p<0.001), shorter length of stay (–25 [63.6] days; p<0.001), fewer inpatient days/month (–3.1 [7.2] days) and one (2.8) additional outpatient visit/month (p<0.001) occurred post-initiation.
Limitations: The absence of a control group in this pre-/post comparison may have resulted in exposure to a regression to the mean effect. Also, this study evaluated only one cohort of patients in a VA healthcare setting.
Conclusions: VA patients with schizophrenia and schizoaffective disorder treated with RLAT experienced fewer hospitalisations and psychiatric-related inpatient days following RLAT initiation. Further studies utilising a control group and in non-VA populations are warranted.
Acknowledgements
Declarations of interest: This research was sponsored by Ortho-McNeil Janssen Scientific Affairs, LLC. M. F. has disclosed that he is a consultant for Ortho-McNeil Janssen and other pharmaceutical companies, and was a member of the speakers’ boards for Ortho-McNeil Janssen and other pharmaceutical companies. K. S. and M. S. have no relevant financial relationships to disclose. P. R. has disclosed that she was a consultant for Ortho-McNeil Janssen Scientific Affairs, LLC on this manuscript. R. D. has disclosed that he is a current employee of Ortho-McNeil Janssen Scientific Affairs, LLC, and a J&J stockholder. S.V. and S. F. have disclosed that they were employees of Ortho-McNeil Janssen Scientific Affairs, LLC, when this analysis was performed. The authors wish to acknowledge the technical and editorial support provided by Matthew Grzywacz, PhD and Helix Medical Communications.